Fanconi anemia (FA) is a human disorder characterized by cancer susceptibility and cellular sensitivity to DNA crosslinks and other damages. Thirteen complementation groups and genes are identified, including BRCA2, which is defective in the FA-D1 group. Eight of the FA proteins, including FANCG, participate in a nuclear core complex that is required for the monoubiquitylation of FANCD2 and FANCI. FANCD2, like FANCD1/BRCA2, is not part of the core complex, and we previously showed direct BRCA2-FANCD2 interaction using yeast two-hybrid analysis. We now show in human and hamster cells that expression of FANCG protein, but not the other core complex proteins, is required for co-precipitation of BRCA2 and FANCD2. We also show that phosphorylation of FANCG serine 7 is required for its co-precipitation with BRCA2, XRCC3 and FANCD2, as well as the direct interaction of BRCA2-FANCD2. These results argue that FANCG has a role independent of the FA core complex, and we propose that phosphorylation of serine 7 is the signalling event required for forming a discrete complex comprising FANCD1/BRCA2-FANCD2-FANCG-XRCC3 (D1-D2-G-X3). Cells that fail to express either phospho-Ser7-FANCG, or full length BRCA2 protein, lack the interactions amongst the four component proteins. A role for D1-D2-G-X3 in homologous recombination repair (HRR) is supported by our finding that FANCG and the RAD51-paralog XRCC3 are epistatic for sensitivity to DNA crosslinking compounds in DT40 chicken cells. Our findings further define the intricate interface between FANC and HRR proteins in maintaining chromosome stability.
Fanconi anemia (FA) is a human disorder characterized by cancer susceptibility and cellular sensitivity to DNA crosslinks and other damages. Thirteen complementation groups and genes are identified, including BRCA2, which is defective in the FA-D1 group. Eight of the FA proteins, including FANCG, participate in a nuclear core complex that is required for the monoubiquitylation of FANCD2 and FANCI. FANCD2, like FANCD1/BRCA2, is not part of the core complex, and we previously showed direct BRCA2-FANCD2 interaction using yeast two-hybrid analysis. We now show in human and hamster cells that expression of FANCG protein, but not the other core complex proteins, is required for co-precipitation of BRCA2 and FANCD2. We also show that phosphorylation of FANCG serine 7 is required for its co-precipitation with BRCA2, XRCC3 and FANCD2, as well as the direct interaction of BRCA2-FANCD2. These results argue that FANCG has a role independent of the FA core complex, and we propose that phosphorylation of serine 7 is the signalling event required for forming a discrete complex comprising FANCD1/BRCA2-FANCD2-FANCG-XRCC3 (D1-D2-G-X3). Cells that fail to express either phospho-Ser7-FANCG, or full length BRCA2 protein, lack the interactions amongst the four component proteins. A role for D1-D2-G-X3 in homologous recombination repair (HRR) is supported by our finding that FANCG and the RAD51-paralog XRCC3 are epistatic for sensitivity to DNA crosslinking compounds in DT40 chicken cells. Our findings further define the Introduction Fanconi anemia (FA) is characterized clinically by progressive aplastic anemia, multiple congenital abnormalities and a predisposition to malignancy including acute myeloid leukaemia and squamous carcinomas of the head and neck (Alter, 1996) . FA cells universally, but not exclusively, display hypersensitivity to DNA interstrand crosslinking agents (Carreau et al., 1999; Kennedy and D'Andrea, 2005) . As we discussed previously , this phenotype is likely due to the absolute dual requirement for RAD51-mediated homologous recombination repair (HRR) and translesion synthesis (TLS) during crosslink repair at broken replication forks (Hinz et al., 2007; Patel and Joenje, 2007) . As many fanc mutants show a suppression of base-substitution mutagenesis (reviewed by Hinz et al., 2006) , it is clear that the 'FA pathway' has a much broader role than promoting just the repair of crosslink damage.
Thirteen FA genes are now identified (Levitus et al., 2006; Smogorzewska et al., 2007) , but the exact mechanistic function of many FA proteins remains unclear. FANCD1 is identified as the breast cancer susceptibility protein BRCA2 (Howlett et al., 2002) , whose role lies in regulating RAD51 in HRR (Davies et al., 2001; Gudmundsdottir and Ashworth, 2006) . BRCA2 function requires a binding partner PALB2 (Xia et al., 2006) , recently identified as FANCN (Reid et al., 2007; Xia et al., 2007) . The FANCA/B/C/E/F/G/ L/M proteins, together with FAAP24/100, are subunits of a nuclear core complex (Mathew, 2006; Ciccia et al., 2007; Ling et al., 2007) required for the interdependent monoubiquitylation of FANCD2 and FANCI (Smogorzewska et al., 2007) .
Increasing evidence implicates FANCD2 and other FANC proteins, including FANCG, being coupled to HRR (Niedzwiedz et al., 2004; Yang et al., 2005; Taniguchi and D'Andrea, 2006) . For example, we previously showed direct interactions between the following pairs of proteins: FANCG-BRCA2; FANCD2-BRCA2; FANCG-XRCC3 (Hussain et al., 2003 (Hussain et al., , 2004 (Hussain et al., , 2006 . XRCC3 is one of five RAD51 paralogs, which have nonredundant roles in HRR (Thacker, 2005) . A reduced efficiency of HRR, measured after the induction of I-SceI-mediated double-strand breaks, was reported in human and chicken fancg mutants (Yamamoto et al., 2003; Nakanishi et al., 2005) . FANCG protein has at least seven tetratricopeptide repeats (TPRs), which are critical for the function of FANCG and its interaction with FANCA, FANCF and the HRR proteins BRCA2 and XRCC3 (Blom et al., 2004; Hussain et al., 2006) . These TPRs indicate that FANCG likely acts as a scaffold for the assembly or stabilization of protein complexes (Lamb et al., 1995; Groves and Barford, 1999) .
FANCA/D1/D2/G/M (Yamashita et al., 1998; Taniguchi et al., 2002; Collins and Kupfer, 2005; Esashi et al., 2005; Meetei et al., 2005) are all phosphoproteins. FANCG phosphorylation occurs at serines 7, 383 and 387, and these modifications are functionally important for cellular resistance to crosslinking damage Qiao et al., 2004) . The mutant FANCG-S7A protein expressed in FA-G EUFA143 lymphoblasts was able to bind and stabilize FANCA and FANCC, although FANCD2 monoubiquitylation was slightly reduced . While it is well established that FANCG is critical for the assembly of a functional FA nuclear core complex (Garcia-Higuera et al., 1999; Waisfisz et al., 1999; Gordon and Buchwald, 2003) , here we define an essential role for FANCG in mediating the key interaction between BRCA2 and FANCD2 (Hussain et al., 2004; Wang et al., 2004) . Moreover, we present evidence that phosphorylation of FANCG at serine 7 is essential, not only for its own direct interactions with BRCA2 and XRCC3, but also the pair-wise interactions among BRCA2, FANCD2 and XRCC3. We propose that this new complex consisting of at least these four FANC and HRR proteins (D1-D2-G-X3) is responsible for promoting the HRR component of crosslink repair.
Results
Interaction between BRCA2 and FANCD2 is dependent on FANCG, but not other core complex proteins We previously demonstrated that FANCD2 and BRCA2 co-immunoprecipitated in wild-type mammalian cells and that co-precipitation was absent in two FA-G lymphoblast cell lines (Hussain et al., 2004) . The interaction was further investigated by examining other FA complementation groups. BRCA2 co-immunoprecipitated using FANCD2 antisera in both wild-type cells (HeLa and CRL-1583) and cells from groups FA-A/C/ E/F (Figure 1a) , while it was absent in FA-D2 cells (PD20). Western blotting confirmed that each FA cell line utilized failed to express detectable levels of the respective FA protein (data not shown). Co-precipitation between FANCD2-BRCA2 failed to occur in CHO FancG mutants NM3 and KO40, and in human FA-G fibroblast (326SV) and lymphoblast (EUFA143) cells (Figure 1b) . Introduction of wild-type FANCG (either human cDNA or genomic hamster for 40BP6), and expression of FANCG protein in the four cell lines restored the interaction of FANCD2-BRCA2. The coprecipitation of FANCD2-BRCA2 was also present when cell extracts were incubated with DNase prior to performing the immunoprecipitation (data not shown).
As FANCD2-BRCA2 co-precipitated in human FA-A/C/E/F cells, that fail to monoubiquitylate FANCD2 (Gregory et al., 2003) , we sought to determine which isoform(s) of FANCD2 interact with BRCA2. We utilized a FA-D2 cell line PD20 that has been transfected with K561R-FANCD2 (Garcia-Higuera et al., 2001 ) and therefore expresses a FANCD2 protein that cannot be monoubiquitylated (Figure 2a ). Coprecipitation of BRCA2 with FANCD2 was observed in wild-type cell lines and PD20-3-15 (functionally complemented with human chromosome 3p) and also in PD20 þ K561R-FANCD2 and an additional FA-A cell line (HCS72). This result confirms that FANCD2-S interacts with BRCA2 in vivo (Figure 2b ). Interaction between BRCA2 and FANCD2-L (Wang et al., 2004) was corroborated in a reciprocal experiment using BRCA2 antibody (Figure 2c ). Neither FANCD2 isoform co-precipitated with BRCA2 in FancG mutants NM3, KO40 and UV40. The two isoforms of FANCD2 can be distinguished in the wild-type cells, but only FANCD2-S co-precipitated with BRCA2 in human cells of complementation groups FA-A/C/E/F as expected ( Figure 2c ).
The role of FANCG phosphorylation in mediating the interaction between FANCD2 and BRCA2 Transduction of NM3 and EUFA143 with human FANCG cDNA mutated at phosphorylation sites S7, S383 and S387 (substituted with alanine), results in only partial correction of their mitomycin C (MMC) hypersensitivity Qiao et al., 2004) , so we examined FANCD2-BRCA2 co-precipitation in these cell lines (Figure 3 ). BRCA2 co-precipitated using FANCD2 antisera in AA8, 40BP, NM3 þ FANCG and the two 'mitotic' mutants NM3 þ S383A and NM3 þ S387A (Figure 3a ). Even mutation of FANCG at both S383 and S387 failed to disrupt the interaction between BRCA2-FANCD2 ( Figure 3a , lane 9). In contrast, BRCA2 failed to co-precipitate in NM3 expressing the FANCG-S7A protein or in NM3 with empty pMMP vector. Identical results were observed in human cells, with co-precipitation of BRCA2 and FANCD2 in all cell lines tested, except EUFA143 þ vector, EUFA143 þ S7A and PD20 (Figure 3b ). Thus, BRCA2 and FANCD2 failed to co-precipitate in both hamster and human cell lines that express FANCG-S7A, indicating that phosphorylation of Ser7 is most likely Figure 3 Phosphorylation of FANCG at serine 7 is required for the interaction of FANCD2 and BRCA2. The generation of NM3 and EUFA143 cell lines expressing human FANCG protein with mutations in the phosphorylation sites at serines 7, 383 and 387 was described previously Qiao et al., 2004) . The level of expression of the various forms of the FANCG protein in both sets of NM3 and EUFA143 are similar and this was confirmed here (data not shown). These cell lines show intermediate sensitivity to MMC. In NM3, the D 37 values of the various cell lines following treatment with MMC were: required for FANCG protein to mediate the interaction between BRCA2-FANCD2.
Phosphorylation of Serine 7 is required for FANCG interaction with BRCA2 and XRCC3, but not the core complex proteins FANCA and FANCF As FANCG-S7A fails to mediate the interaction between FANCD2 and BRCA2 in vivo, we next determined whether this phosphomutant co-precipitated with FANCA, FANCF, BRCA2 and XRCC3, all of which directly interact with FANCG. We tested for coimmunoprecipitation of the various phosphomutant forms of FANCG in whole cell extracts from cells treated with 50 nM MMC ( Figure 4 ). The S7A mutant form of FANCG failed to co-precipitate with BRCA2 in NM3 þ S7A and EUFA143 þ S7A cells ( Figure 4a , lanes 3 and 11). Cells expressing the S383A and S387A forms of FANCG did show co-precipitation with BRCA2 ( Figure 4a , lanes 5, 6, 13 and 14). Coprecipitation was present in positive control cell lines (including NM3 þ FANCG and EUFA143 þ FANCG), but absent in negative controls.
The interactions of XRCC3 with the mutant forms of FANCG were identical to that shown by BRCA2 ( Figure 4b ). XRCC3 was found to co-precipitate in NM3 and EUFA143 cell lines expressing the wild-type, S383A and S387A forms of the FANCG protein ( Figure 4b , lanes 4-6, 12-14), but was absent in NM3 þ S7A and EUFA143 þ S7A cells (Figure 4b , lanes 3 and 11). In addition, co-precipitation of FANCG and XRCC3 was observed in wild-type cells (AA8, V79, BD180 and HeLa), HSC72 (FA-A) and PD20 (FA-D2), but was absent in NM3 þ vector, EUFA143 þ vector and Xrcc3 mutant irs1SF.
In contrast, co-precipitation of FANCG with FANCA and FANCF was observed in all NM3 and EUFA143 cell lines expressing a FANCG protein, including FANCG-S7A (Figures 4c and 4d, lanes 3  and 11) . Indeed, co-precipitation of FANCG-FANCA and FANCG-FANCE was only absent in the respective mutant cell lines HSC72 (FA-A) and EUFA121 (FA-F), NM3 þ vector, EUFA143 þ vector and KO40. Co-precipitation of FANCG-S7A with FANCA and FANCC was previously demonstrated in EUFA143 þ S7A cells . Therefore, phosphorylation of Ser7 appears required for FANCG's interaction with the HRR proteins BRCA2 and XRCC3 in vivo, but not for interaction with the FA core complex proteins FANCA and FANCF.
BRCA2 is required for complex formation amongst FANCD2, FANCG and XRCC3
Having established that phosphorylation of FANCG at Ser7 was required for its own interaction with BRCA2 and XRCC3, and for the co-precipitation of BRCA2-FANCD2, we further investigated the interactions between these four proteins. We previously described the co-precipitation of BRCA2-XRCC3 (Hussain et al., 2006), and we can also now report the co-precipitation of FANCD2 with both FANCG and XRCC3 in hamster and human cells ( Figure 5 , lanes 1, 4 and 5). While a direct interaction between FANCG and FANCD2 has not been reported, both interact directly with BRCA2 (de Winter et al., 1998; Hussain et al., 2003 Hussain et al., , 2004 . Each of these four proteins can therefore be co-precipitated with the other three, suggesting that they exist together in a single protein complex (D1-D2-G-X3). Besides being required for co-precipitation of BRCA2-FANCD2 (Figures 1-3) , FANCG is also required for the co-precipitation of BRCA2-XRCC3 (Hussain et al., 2006) and FANCD2-XRCC3 ( Figure 5 , lanes 6 and 7). We next determined whether BRCA2 or XRCC3 were also required for the formation of the D1-D2-G-X3 complex. To achieve this we examined co-precipitation of pairs of proteins in cell lines mutant for BRCA2 (hamster V-C8 and human CAPAN-1) and XRCC3 (irs1SF). XRCC3 was not required for the co-precipitation of BRCA2-FANCD2, FANCG-BRCA2 or FANCG-FANCD2 (Figure 5a ). Each of these pairs of proteins co-precipitated in irs1SF ( Figure 5 , lane 2) and the positive controls ( Figure 5, lanes 1, 3 and 4) . We similarly determined that co-precipitation between FANCG-BRCA2, FANCG-XRCC3 and BRCA2-XRCC3 was present in PD20 cells (Figure 4b and data not shown), indicating that FANCD2 was not required for these interactions. However, as co-precipitation of FANCG-XRCC3, FANCG-FANCD2 and FANCD2-XRCC3 was absent in both V-C8 and CAPAN-1 cells ( Figure 5, lanes 8 and 9) , and that both these cell lines are predicted to express truncated BRCA2 (Goggins et al., 1996; Wiegant et al., 2006) , full length BRCA2 protein would seem to be required for each of these interactions, and thus also for the formation of the D1-D2-G-X3 protein complex.
Interactions of phospho-Ser7-FANCG
Having established that FANCG-S7A fails to co-precipitate with BRCA2, FANCD2 and XRCC3, we next examined the interactions of the endogenous phospho-S7-FANCG (FANCG S7-P ) protein using a phospho-specific antibody raised against phosphoserine 7 of FANCG . This antibody does not detect FANCG-S7A and treatment of extracts with phosphatase abolishes its ability to detect wild-type FANCG. Immunoprecipitation was performed with antibodies to BRCA2, FANCD2, FANCA, XRCC3 and FANCG itself and subsequently immunoblotted with either the phospho-specific antibody (Figure 6a , lanes 5-8) or the standard/nonspecific anti-FANCG as a control (Figure 6a, lanes 1-4) . Blotting with the phospho-specific antisera confirmed that FANCG S7-P does co-precipitate with BRCA2, FANCD2 and XRCC3 in AA8 and NM3 þ FANCG cells (Figure 6a , lanes 5 and 8). The specificity of the antibody was confirmed by immunoprecipitating with nonspecific anti-FANCG. The phospho-specific antibody failed to detect FANCG-S7A (Figure 6a, lane 7) , while it was detected using the nonspecific FANCG antibody (Figure 6a, lane 3) .
Interestingly, the phospho-specific antibody failed to detect FANCG following immunoprecipitation with anti-FANCA (Figure 6a, lanes 5 and 8) , while interaction between FANCA and FANCG was clearly observed using the nonspecific antibody (Figure 6a,  lanes 1, 3 and 4) . To confirm the lack of interaction of FANCG S7-P and FANCA we used increased doses of MMC (Figure 6b only appears to interact with FANCA at higher levels of MMC-induced DNA damage, and at a dose where less than 10% of cells remain viable. In contrast, immunoprecipitation between BRCA2 and FANCG S7-P was observed at all doses, including untreated cells.
The D1-D2-G-X3 complex is independent of FANCG's interaction with FANCA The lack of interaction between FANCG S7-P and FANCA suggests that the D1-D2-G-X3 complex forms independently of FANCA and is discrete from the FA nuclear core complex. We confirmed this by examining HeLa and AA8 whole cell extracts for the presence of FANCG S7-P , BRCA2 and XRCC3 by western blotting, after they had been immunodepleted of FANCA. We performed two successive immunoprecipitations with antisera to FANCA to deplete extracts of FANCG protein bound to FANCA, and then performed a third IP with the nonspecific/standard FANCG antibody (Figure 7) . Therefore, three immunoprecipitates were produced for each extract: (A) after IP with (Figure 7 , lanes 3 and 6) reveals the presence of FANCG protein, which is detected using both the nonspecific and phospho-specific antibodies. Also present were BRCA2 and XRCC3, indicating that these were in complex with the FANCG protein that remained (presumably FANCG S7-P ) following the depletion of FANCA.
FANCG Ser7-phosphorylation is ATR-dependent
The kinase that phosphorylates FANCG at Ser7 remains to be determined . Given that phosphatidylinositol-3 kinase related kinases (PIKK) ATR and ATM have been shown to phosphorylate FANCD2 Ho et al., 2006) , we investigated their possible role in the phosphorylation of FANCG. Expression of FANCG S7-P was determined by western blotting in wild-type (GM02188), ataxia telangiectasia (AT) and ATR-Seckel cells (O'Driscoll et al., 2003; Alderton et al., 2004) following treatment with 50 nM MMC, with and without the addition of the PIKK inhibitor wortmannin. Wortmannin has been shown to inhibit ATM at a dose of 20 mM, while ATR is inhibited at doses from 100 mM (Sarkaria et al., 1998) . We failed to detect FANCG S7-P in (Figure 8a , lanes 4-6). Expression of FANCG was detected using the nonspecific antibody, indicating that Ser7 is not phosphorylated in ATR-Seckel cells. Contrastingly, expression of FANCG S7-P was detected in wild-type and ATM-deficient cells, including those treated with 20 mM wortmannin (Figure 8a, lanes 1, 2,  7 , and 8). Expression did appear reduced in cells treated with 100 mM wortmannin (Figure 8a, lanes 3 and 9) , a dose reported to inhibit ATR. These data suggest that phosphorylation at Ser7 occurs in an ATR-dependent manner. Either ATR phosphorylates FANCG directly, or it may be phosphorylated by a kinase downstream of ATR, such as CHK1. We also found that when wildtype human and hamster cells were incubated with 200 mM wortmannin, co-precipitation of FANCG with BRCA2 or XRCC3 was not observed (data not shown). Consistent with this observation, treatment of wild-type and EUFA143 þ FANCG cells abolished the co-precipitation of FANCD2 and BRCA2 (Figure 8b ).
ATR-Seckel cells in two independent experiments

Xrcc3 and FancG are epistatic for interstrand crosslink sensitivity in DT40 cells
If the putative D1-D2-G-X3 complex is responsible for promoting the HR component of crosslink repair, mutations abolishing FANCG and XRCC3 are expected to behave in an epistatic manner in response to crosslinking agents. The genetic relationship between FANCG and XRCC3 was investigated by determining the cisplatin and MMC sensitivity of knockout mutants created in chicken DT40 cells, whose properties make them amenable to determining genetic interactions (Takata et al., 2001; Yamashita et al., 2002; Niedzwiedz et al., 2004) . Double mutants of fancg and xrcc3 were made by disrupting FANCG in a conditional xrcc3 background, followed by excision of the Xrcc3-EGFP expression cassette by activating MerCreMer recombinase (Zhang et al., 1998) . The removal was ensured by subcloning and was further verified by the loss of GFP fluorescence and by Southern blotting using human XRCC3 probe (data not shown). Mutant xrcc3 cells show a greater sensitivity to killing by cisplatin compared to fancg cells in a clonal assay (Figure 9a) . However, two independent clones of xrcc3/fancg cells display the same cisplatin sensitivity as the xrcc3 single mutant. To confirm epistasis, we examined growth inhibition by MMC (Figure 9b ). The xrcc3 cells showed greater sensitivity to MMC than fancg cells (50% growth inhibition at 4.5 and 12 nM, respectively, compared to 65 nM for wild-type cells). The responses of xrcc3 and xrcc3/fancg cells were the same, demonstrating epistasis and a functional overlap between FANCG and XRCC3 in this model system.
Discussion
We showed that the key FANCD2-BRCA2 interaction requires FANCG. FANCD2-BRCA2 co-precipitation in cells from complementation groups FA-A/C/E/F (and also in PD20 þ K561R cells) indicates that FANCD2-S, in addition to the monoubiquitylated isoform (Wang et al., 2004) , interacts with BRCA2, which is consistent with our earlier finding that nonmonoubiquitylated FANCD2 and BRCA2 interact directly in the yeast two-hybrid system (Hussain et al., 2004) . Importantly, these results also show that FANCD2 interacts with BRCA2 independently of the FA nuclear core complex, which may seem counterintuitive because FANCD2-L has been perceived to be the active isoform for 'FA pathway' function (Wang et al., 2004) . We address this apparent paradox below, but first we propose that this interaction regulates the activity and/or subcellular localization of BRCA2, which becomes active in chromatin upon the critical FANCD2-FANCI interdependent monoubiquitylation step(s) (Wang et al., 2004; Smogorzewska et al., 2007) . Phosphorylation of FANCG-S7 is essential for the direct FANCD2-BRCA2 interaction, as well as for the interactions of FANCG with BRCA2, XRCC3 and FANCD2 (see Table 1 summary). Commensurate with FANCG's proposed role in assembling multi-protein complexes, FANCG S7-P is also required for the interactions of BRCA2-XRCC3 and FANCD2-XRCC3 (Table 1) . However, FANCG S7-P is not required for protein interactions in the core complex, since FANCG-S7A co-precipitates with core complex proteins FANCA/C/F (Table 1) , and we only detect an interaction of FANCG S7-P with FANCA in cells exposed to excess MMC (Figure 6b ). Our studies point to the existence of a protein complex (D1-D2-G-X3) comprising FANCG, the RAD51 paralog XRCC3 and two noncore complex FA proteins, FANCD1/BRCA2 and FANCD2. Evidence for a functional link between XRCC3 and some components of the Fanconi pathway is further suggested by our finding that Xrcc3 and FancG are epistatic for crosslinker sensitivity in DT40 chicken cells. Moreover, D1-D2-G-X3 complex formation occurs independently of FANCD2 monoubiquitylation and other core complex proteins, but depends on FANCG S7-P and full length BRCA2. We propose a model in which binding of FANCG S7-P to BRCA2 is the critical event in forming the D1-D2-G-X3 complex. We found that ATR-Seckel cells lack FANCG S7-P and that wortmannin inhibits this phosphorylation. Because S7 phosphorylation occurs in S-phase, and is DNA-damage inducible , the ATR kinase is the likely candidate for performing this step.
There has been much conjecture and conflicting results in the literature on the involvement of the FA proteins in HRR (and single-strand annealing based on HRR) of I-SceI induced DNA double strand breaks (DSBs) in artificial direct-repeat substrates (Niedzwiedz et al., 2004; Bridge et al., 2005; Nakanishi et al., 2005; Ohashi et al., 2005; Taniguchi and D'Andrea, 2006) . Such a defect in FA cells is typically small or absent compared to that in mutants of BRCA2 and RAD51 paralogs as discussed in detail (Hinz et al., 2006) . Moreover, given that most FA cell lines show a modest or no sensitivity to agents that induce direct DSBs, the relevance of I-SceI-based HRR assays to crosslink repair is not clear. Models for interstrand crosslink repair at replication forks propose that HRR acts in conjunction with crosslink unhooking by ERCC1-XPF and translesion synthesis in order to restart replication, with FA proteins mediating these processes (Dronkert and Kanaar, 2001; Thompson, 2005; Thompson et al., 2005; Mirchandani and D'Andrea, 2006; Niedernhofer, 2007; Patel and Joenje, 2007; Zhang et al., 2007) . Data from the CHO hamster model system argue strongly that the FA 'pathway' is important for diverse damages that cause blocked or broken replication forks (Wilson et al., 2001; Tebbs et al., 2005; Hinz et al., 2007) . XRCC3 is required for replication fork slowing on cisplatin (a crosslinker)-damaged chromosomes (Henry-Mowatt et al., 2003) . In the light of our findings of Xrcc3/FancG epistasis and the direct XRCC3-FANCG interaction, the D1-D2-G-X3 complex may control this modulation of fork progression. Other proteins, such as FANCE, RAD51C It was previously shown that FANCG-S7A co-precipitates with FANCC . and PALB2/FANCN, may associate with the D1-D2-G-X3 complex. FANCE directly interacts with FANCD2 and co-immunoprecipitates with BRCA2 (Pace et al., 2002; Wang et al., 2004) , RAD51C is the direct binding partner of XRCC3 in one of two distinct RAD51 paralog complexes Liu et al., 2002; Yamada et al., 2004) and PALB2 enables key biochemical functions of BRCA2 (Xia et al., 2006) . The dual requirement for HRR and TLS during crosslink repair may be envisioned as follows with respect to the two major FANCG-containing protein complexes such that the FA 'pathway' facilitates crosslink repair in a branched manner. The newly identified (minimal) D1-D2-G-X3 complex likely serves to initiate or modulate HRR at broken replication forks in a FANCD2-FANCI monoubiquitylation-dependent manner (Smogorzewska et al., 2007) , whereas the FANCA/B/C/E/F/G/L/M/FAAP24/ FAAP100 core complex (which is required for this monoubiquitylation) promotes TLS. Mutant fancg human and hamster cells expressing FANCG-S7A protein retain core complex formation and display sensitivity to MMC that is intermediate between that of wild-type and fancg null cells . This genetic separation of FANCG function is consistent with our hypothesis that there is an intact TLS pathway in FANCG-S7A expressing cells, which presumably lack the functionality of D1-D2-G-X3 in HRR.
The concept of a FA 'pathway', which branches into HR and TLS components that can operate independently, downstream of an intact nuclear core complex, in the repair of interstrand crosslinks (Wang, 2007) is consistent with data for other DNA lesions. For example, hamster fancg cells have significant hypersensitivity to killing by simple alkylating agents (ENU, MMS), UV-C and bleomycin (Wilson et al., 2001; Tebbs et al., 2005) , while several human complementation groups, including FA-G cells, also show appreciable bleomycin and MMS sensitivity (Carreau et al., 1999) . We propose that this enhanced killing may be attributed to compromised HR repair of broken replication forks in the FANCG-defective cells. Conversely, reduced hprt mutagenesis observed in hamster fancg cells after ENU and UV-C, results from loss of FANCG-mediated TLS (Hinz et al., 2006 (Hinz et al., , 2007 . This branched role of the FA pathway in HR-mediated repair of broken replication forks was also recently discussed in the context of a requirement for gH2AX (Lyakhovich and Surralles, 2007) , which interacts with FANCD2 in a UV-C and BRCA1 dependent manner (Bogliolo et al., 2007) .
In conclusion, our studies indicate a function for FANCG that is distinct from its role in the nuclear core complex. It is apparent that protein-protein interactions mediated by FANCG depend on its TPR motifs (Hussain et al., 2006) , which act as scaffolds to facilitate two functionally discrete complexes, the core complex and D1-D2-G-X3. The assembly of this latter complex depends on ATR-mediated FANCG Ser7 phosphorylation, suggesting that discrete phosphorylation sites determine the separate functions of FANCG. Our studies indicate that the functional link between certain FA proteins and HRR extends beyond the interaction of monoubiquitylated FANCD2-FANCI and BRCA2. A 'replication restart complex', comprising at least D1-D2-G-X3 likely promotes HRR and cell survival in response to replication forks that break upon encountering DNA damage.
Materials and methods
Cell lines
Chinese hamster ovary (CHO) cell line AA8 and derived mutants UV40, NM3 and irs1SF (Xrcc3-mutated) have been described previously (Busch et al., 1996; Liu et al., 1998; Lamerdin et al., 2004) . KO40 is a FancG knockout (Tebbs et al., 2005) and 40BP6 is its complemented counterpart (corrected with genomic CHO FancG). Human cell lines HeLa and CRL-1583, the FA cell lines 326SV (FA-G), PD20 (FA-D2) and complemented counterparts 326SV þ FANCG, PD20-3-15, PD20 þ K561R-FANCD2 have been described (Whitney et al., 1995; Garcia-Higuera et al., 2001; Hussain et al., 2004; Qiao et al., 2004) . Hamster V-C8 and human CAPAN-1 cells, mutant for BRCA2, have been described (Goggins et al., 1996; Wiegant et al., 2006) . Fibroblast cells were maintained as previously described (Johnson and Jones, 1999; Johnson et al., 2000) . Lymphoblastoid BD180, GM02188 (wild-type), GM01389D (ATM-deficient cells) and DK0064 (Seckel syndrome cells with impaired ATR function), and FA cell lines HSC72, BD220 (FA-A), BD215 (FA-C), EUFA409 (FA-E), EUFA121 (FA-F), EUFA673 and EUFA143 (FA-G) were grown in RPMI1640 medium with 15% fetal calf serum. NM3 and EUFA143 cell lines expressing FANCG with phosphorylation site mutations have been described and characterized previously Qiao et al., 2004) . Cell lines were generously provided by Alan D'Andrea (PD20's), Margaret Zdzienicka (V-C8), Penny Jeggo (GM02188/ATM-deficient/ATR-Seckel) and Hans Joenje (some EUFA lines).
Immunoblotting and co-immunoprecipitation
Western blotting was performed as described previously (Wilson et al., 2001) . Antibodies to FANCD2 (ab2187), bactin (ab6276) and IgG (ab6802) were obtained from Abcam Limited (Cambridge, UK) and BRCA-2 antibody (Ab-2) was obtained from Oncogene Research Products (Merck, West Drayton, UK). FANCA, FANCG (H:83-622, R no. 2942-44) and FANCF (H:1-374, R no. 6305-07) antibodies were as described previously (Kupfer et al., 1997; Waisfisz et al., 1999; de Winter et al., 2000) . Preparation of a phospho-specific antibody raised against phosphoserine 7 of FANCG and the XRCC3 antibody (Hussain et al., 2006) were described previously. Co-immunoprecipitation was performed using Sigma's (Poole, UK) EZview red protein affinity gel system (Hussain et al., 2004 (Hussain et al., , 2006 . Total cell extracts were prepared from 1-2 Â 10 7 exponentially growing cells either untreated or treated with MMC for 18 h. Antibodies described above and FANCA-antisera (Abcam Limited, ab5063) were used for immunoprecipitation. For some experiments DNAse at 1 mg ml À1 was added to total cell extracts and incubated at 37 1C overnight prior to the addition of antibody. When used, wortmannin was added to cells 18 h before the preparation of extracts.
Chicken DT40 cell lines and gene targeting
The xrcc3 cell line and the subsequent generation of a conditional xrcc3-deficient DT40 cell line were previously described (Takata et al., 1998; Hirano et al., 2005) . This cell line harbours human Xrcc3-IRES-EGFP expression cassette, as well as Cre recombinase fused with the ligand-binding domain of the oestrogen receptor and designated MerCreMer (Zhang et al., 1998) . The FANCG gene was disrupted in this cell line using a FANCG targeting vector (Yamamoto et al., 2003) , then the hXrcc3 expression cassette was deleted by addition of 4-hydroxy tamoxifen, leading to removal of Xrcc3 expression. Cell culture and determination of sensitivity to cisplatin by colony formation was as described (Takata et al., 2001; Yamamoto et al., 2003) . For MMC-induced growth inhibition, 5 Â 10 5 cells were seeded into six-well dishes and surviving cells were counted after 72 h.
